ATE419008T1 - Adjuvante zusammensetzung und anwendungsverfahren dafür - Google Patents

Adjuvante zusammensetzung und anwendungsverfahren dafür

Info

Publication number
ATE419008T1
ATE419008T1 AT05747242T AT05747242T ATE419008T1 AT E419008 T1 ATE419008 T1 AT E419008T1 AT 05747242 T AT05747242 T AT 05747242T AT 05747242 T AT05747242 T AT 05747242T AT E419008 T1 ATE419008 T1 AT E419008T1
Authority
AT
Austria
Prior art keywords
vaccine
adjuvant composition
gammadeltat
directed
present
Prior art date
Application number
AT05747242T
Other languages
German (de)
English (en)
Inventor
Jerome Tiollier
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Application granted granted Critical
Publication of ATE419008T1 publication Critical patent/ATE419008T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT05747242T 2004-04-26 2005-04-25 Adjuvante zusammensetzung und anwendungsverfahren dafür ATE419008T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56495904P 2004-04-26 2004-04-26
US62906904P 2004-11-18 2004-11-18

Publications (1)

Publication Number Publication Date
ATE419008T1 true ATE419008T1 (de) 2009-01-15

Family

ID=34969994

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05747242T ATE419008T1 (de) 2004-04-26 2005-04-25 Adjuvante zusammensetzung und anwendungsverfahren dafür

Country Status (8)

Country Link
US (1) US20070218086A1 (enExample)
EP (1) EP1761278B1 (enExample)
JP (1) JP2007534743A (enExample)
AT (1) ATE419008T1 (enExample)
AU (1) AU2005235271A1 (enExample)
CA (1) CA2564562A1 (enExample)
DE (1) DE602005012097D1 (enExample)
WO (1) WO2005102385A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212666D0 (en) * 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
US20070134273A1 (en) * 2004-02-10 2007-06-14 Francois Romagne Composition and method for the treatment of carcinoma
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
BRPI0608926A2 (pt) * 2005-03-22 2010-11-03 Innate Pharma ativador de células t gamadelta, composição farmacêutica, uso de um ativador de células t gamadelta, composição de vacina, método de ativação de uma célula t gamadelta, célula t gamadelta, e, uso de uma célula t gamadelta
GB2443591B (en) * 2005-09-07 2010-04-28 Secr Defence Adjuvanted vaccine
ITMI20060366A1 (it) * 2006-03-01 2007-09-02 C4T S C A R L Composti organo tiopirosfosfati metodo per prepararli e composizioni che li contengono
EP1878440A1 (en) * 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
WO2008012538A2 (en) * 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
EP2123285A1 (en) * 2008-05-21 2009-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleosidic phosphoantigens for use in VGAMMA9DELTA2 T cell-mediated therapy
US8735624B2 (en) 2008-09-10 2014-05-27 Innate Pharma Polymorphic form of CHDMAPP, method of preparation thereof, and pharmaceutical composition comprising same
CA2738769C (en) * 2008-09-29 2016-02-09 Cadila Pharmaceuticals Ltd. Farnesoid-x-receptor antagonist as a vaccine adjuvant
GB0901411D0 (en) * 2009-01-29 2009-03-11 Secr Defence Treatment
US10226528B2 (en) 2013-03-15 2019-03-12 The Trustees Of The University Of Pennsylvania Vaccines with biomolecular adjuvants
KR102451441B1 (ko) * 2020-06-25 2022-10-12 대한민국 신규 면역증강제 및 이를 포함하는 백신 조성물
CN115916255A (zh) * 2020-06-26 2023-04-04 大韩民国(动植物检疫局) 新型免疫刺激剂和包含其的疫苗组合物
IL309249A (en) * 2021-06-28 2024-02-01 Byondis Bv Conjugates including phosphoantigens and their use in therapy
GB202114311D0 (en) * 2021-10-06 2021-11-17 Molecular Attraction Ab New compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5639653A (en) 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1998050567A1 (en) 1997-05-02 1998-11-12 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
BE1011282A3 (fr) * 1997-07-14 1999-07-06 Solvay Composition a base de polyethylene et procede de fabrication d'objets faconnes a partir de la composition.
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
FR2782722B1 (fr) * 1998-09-01 2001-01-12 Inst Nat Sante Rech Med Nouveaux composes phosphoepoxydes, procede de fabrication et applications
FR2782721B1 (fr) 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Nouveaux composes phosphohalohydrines, procede de fabrication et applications
WO2003009855A2 (de) * 2001-07-20 2003-02-06 Bioagency Ag Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
EP1434859A2 (en) 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
WO2003038072A1 (en) * 2001-10-31 2003-05-08 Universite Libre De Bruxelles Generation and use of new types of dendritic cells
FR2833266B1 (fr) 2001-12-11 2004-10-22 Mayoly Spindler Lab Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2
ATE441420T1 (de) 2002-12-02 2009-09-15 Innate Pharma Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen
WO2005021708A2 (en) * 2003-05-16 2005-03-10 University Of Maryland Biotechnology Institute Bisphosphonates for prophylaxis and therapy against bioterrorism agents
BRPI0417088A (pt) 2003-12-02 2007-03-13 Innate Pharma ativador de célula t gama delta, composição farmacêutica, uso do ativador de célula t gama delta, composição de vacina, métodos para preparar um composto, e para ativar uma célula t gama delta, célula t gama delta, e, uso da mesma

Also Published As

Publication number Publication date
US20070218086A1 (en) 2007-09-20
AU2005235271A1 (en) 2005-11-03
DE602005012097D1 (de) 2009-02-12
EP1761278A1 (en) 2007-03-14
EP1761278B1 (en) 2008-12-31
WO2005102385A1 (en) 2005-11-03
JP2007534743A (ja) 2007-11-29
CA2564562A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
ATE419008T1 (de) Adjuvante zusammensetzung und anwendungsverfahren dafür
ATE426412T1 (de) Adjuvante influenza-vakzine
EA200800812A1 (ru) Композиции антитела против cd3
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
DE602004028468D1 (de) Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke
EA200702402A1 (ru) Агенты, связывающие склеростин
NO20071604L (no) Loxapinanaloger og fremgangsmater for anvendelse derav.
NO20070699L (no) Spesielle aminoalkylglukosaminidfosfatforbindelser og deres anvendelse
EA200801427A1 (ru) Молекулы антитела со специфической активностью в отношении интерлейкина-6 (ил-6) человека
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
DK1718677T3 (da) Monovalente antistoffragmenter egnede som terapeutiske midler
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
MX2007002787A (es) Adyuvante de glicosilceramida para antigenos de sacarido.
DK1668001T3 (da) Substituerede heteroarylbenzofuransyrer
NO20071937L (no) Fremgangsmater og mellomprodukter for fremstilling av cysteinproteaseinhibitorer
EA200701305A1 (ru) Иммуногенные композиции, содержащие циклические пептиды, полученные из бета-амилоидного пептида
ATE497492T1 (de) Reinigung von montelukast
AR059851A1 (es) Anticuerpos de la egfl7 y metodos de uso
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
ATE513561T1 (de) Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien
WO2006067635A3 (en) USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
NO20062579L (no) Preparater som omfatter melittin-avledede peptider og fremgangsmate for styrking av immunresponser mot malantigener

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1761278

Country of ref document: EP

REN Ceased due to non-payment of the annual fee